300406.SZ
九强生物
SZSE · Healthcare · C 制造业 · CN
CNY 11.51
−1.62%Year over year
Reported trailing growth
- Revenue
- -13.5%
- EBITDA
- —
- EBIT
- -54.7%
- EPS
- -57.6%
- Free cash flow
- -10.2%
- Operating cash flow
- -11.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -3.6%
- EBITDA
- -15.6%
- EBIT
- -19.7%
- Net income
- -21.3%
- EPS
- -21.8%
- Free cash flow
- +20.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026